Peritoneal Carcinoma Clinical Trials

74 recruitingLast updated: June 20, 2026

There are 74 actively recruiting peritoneal carcinoma clinical trials across 22 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 3, Early Phase 1, Phase 4. Top locations include New York, New York, United States, Pittsburgh, Pennsylvania, United States, Houston, Texas, United States. Updated daily from ClinicalTrials.gov.


Peritoneal Carcinoma Trials at a Glance

74 actively recruiting trials for peritoneal carcinoma are listed on ClinicalTrialsFinder across 6 cities in 22 countries. The largest study group is Phase 2 with 36 trials, with the heaviest enrollment activity in New York, Pittsburgh, and Houston. Lead sponsors running peritoneal carcinoma studies include National Cancer Institute (NCI), Mayo Clinic, and M.D. Anderson Cancer Center.

Browse peritoneal carcinoma trials by phase

Treatments under study

About Peritoneal Carcinoma Clinical Trials

Looking for clinical trials for Peritoneal Carcinoma? There are currently 3 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Peritoneal Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Peritoneal Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 74 trials

Recruiting
Phase 2

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Malignant Female Reproductive System Neoplasm+12 more
National Cancer Institute (NCI)2,900 enrolled479 locationsNCT05564377
Recruiting
Phase 2

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

Recurrent Ovarian CarcinomaRecurrent Endometrial CarcinomaRecurrent Fallopian Tube Carcinoma+1 more
National Cancer Institute (NCI)165 enrolled296 locationsNCT05554328
Recruiting
Phase 2

Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

PARP InhibitorPlatinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Primary Peritoneal Carcinoma+1 more
Ronald Buckanovich48 enrolled1 locationNCT05538091
Recruiting
Phase 2Phase 3

Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

Gastroesophageal Junction AdenocarcinomaPeritoneal CarcinomatosisGastric Adenocarcinoma
ECOG-ACRIN Cancer Research Group148 enrolled55 locationsNCT07001748
Recruiting
Phase 2

ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer

Recurrent Ovarian CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Primary Peritoneal Carcinoma+7 more
Ira Winer62 enrolled2 locationsNCT04055649
Recruiting
Phase 2

Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer

Gastric CancerPeritoneal Carcinomatosis
University of Chicago21 enrolled1 locationNCT04107077
Recruiting
Phase 1Phase 2

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Triple-Negative Breast CancerEndometrial CancerPrimary Peritoneal Carcinoma+12 more
Genmab884 enrolled66 locationsNCT05579366
Recruiting
Phase 3

Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

Ovarian CancerPrimary Peritoneal CarcinomaFallopian Tube Cancer+1 more
Imunon500 enrolled7 locationsNCT06915025
Recruiting
Phase 2

A Study of Lorigerlimab in Participants With Advanced Solid Tumors

Endometrial CancerPlatinum Resistant Ovarian CancerPlatinum-Resistant Fallopian Tube Carcinoma+8 more
MacroGenics80 enrolled16 locationsNCT06730347
Recruiting
Phase 2

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

Platinum-Sensitive Ovarian CarcinomaRecurrent Ovarian CarcinomaRecurrent Fallopian Tube Carcinoma+12 more
Roswell Park Cancer Institute80 enrolled2 locationsNCT05231122
Recruiting
Phase 1Phase 2

Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2

Primary Peritoneal CarcinomaFallopian Tube CarcinomaEpithelial Ovarian Cancer+1 more
Beijing Biotech36 enrolled1 locationNCT07617753
Recruiting
Phase 1

Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Associated With Systemic Chemotherapy in Women With Advanced Ovarian Cancer

Peritoneal CarcinomatosisMetastatic Ovarian CarcinomaMetastatic Malignant Neoplasm in the Peritoneum+4 more
Hospices Civils de Lyon15 enrolled6 locationsNCT04811703
Recruiting
Phase 2

A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery

Ovarian CancerPeritoneal Carcinomatosis
Oncoinvent Solutions AS114 enrolled10 locationsNCT06504147
Recruiting
Phase 2

The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas

Breast CarcinomaUrothelial CarcinomaOvarian Carcinoma+26 more
Mayo Clinic27 enrolled1 locationNCT07285044
Recruiting
Not Applicable

A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)

Ovarian CancerOvarian CarcinomaPrimary Peritoneal Carcinoma+11 more
Memorial Sloan Kettering Cancer Center35 enrolled7 locationsNCT05429970
Recruiting
Phase 2

Technical Feasibility of Modified Early Post-Operative Intraperitoneal Chemotherapy (mEPIC)

Peritoneal CarcinomatosisColorectal Cancer MetastaticAppendiceal Neoplasms
Ciusss de L'Est de l'Île de Montréal25 enrolled1 locationNCT05913674
Recruiting

Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study

Ovarian CarcinomaRecurrent Ovarian CarcinomaRecurrent Malignant Solid Neoplasm+7 more
University of Washington2,000 enrolled1 locationNCT06295965
Recruiting
Phase 1

Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies

Colorectal, CancerOvarian CancerPeritoneal Carcinomatosis+4 more
National Cancer Institute (NCI)60 enrolled1 locationNCT04847063
Recruiting
Phase 1

Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF

Breast CarcinomaOvarian CarcinomaPrimary Peritoneal Carcinoma+5 more
M.D. Anderson Cancer Center300 enrolled1 locationNCT03604315
Recruiting
Phase 1

Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers

Metastatic Endometrial CarcinomaStage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8+8 more
National Cancer Institute (NCI)42 enrolled6 locationsNCT05691504